Avalo Therapeutics (AVTX) Other Operating Expenses (2017 - 2024)
Avalo Therapeutics posted quarterly Other Operating Expenses of $87000.0 for Q4 2024, down 97.64% year-on-year from $3.7 million in Q1 2024, and up 112.18% on a QoQ basis from -$714000.0 in Q3 2024.
Avalo Therapeutics (AVTX) has 7 years of Other Operating Expenses data on file, last reported at $87000.0 in Q4 2024.
- For the quarter ending Q4 2024, Other Operating Expenses fell 97.64% year-over-year to $87000.0; the trailing twelve-month figure through Sep 2025 stood at $87000.0 (down 99.72% YoY), and the FY2024 full-year result was $27.3 million, up 425.43% from the prior year.
- Other Operating Expenses for Q4 2024 stood at $87000.0, up from -$714000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $27.5 million in Q1 2024 and bottomed at -$714000.0 in Q3 2024.
- The 4-year median for Other Operating Expenses is $655500.0 (2021), against an average of $2.5 million.
- Peak annual rise in Other Operating Expenses reached 4883.3% in 2024, while the deepest fall reached 389.07% in 2024.
- A 4-year view of Other Operating Expenses shows it stood at $691000.0 in 2021, then fell by 10.27% to $620000.0 in 2022, then surged by 494.52% to $3.7 million in 2023, then tumbled by 97.64% to $87000.0 in 2024.
- The last three Other Operating Expenses figures came in at $87000.0 (Q4 2024), -$714000.0 (Q3 2024), and $446000.0 (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 87,000.00 |
| Sep 30, 2024 | -714,000.00 |
| Jun 30, 2024 | 446,000.00 |
| Mar 31, 2024 | 27.46 Mn |
| Dec 31, 2023 | 3.69 Mn |
| Sep 30, 2023 | 247,000.00 |
| Jun 30, 2023 | 708,000.00 |
| Mar 31, 2023 | 551,000.00 |
| Dec 31, 2022 | 620,000.00 |
| Sep 30, 2022 | 528,000.00 |
| Jun 30, 2022 | 1.57 Mn |
| Mar 31, 2022 | 758,000.00 |
| Dec 31, 2021 | 691,000.00 |
| Sep 30, 2021 | 1.34 Mn |
| Jun 30, 2021 | 511,000.00 |
| Mar 31, 2021 | 936,000.00 |
| Dec 31, 2019 | 1.00 |
| Jun 30, 2019 | 1.28 Mn |
| Mar 31, 2019 | -20,940.00 |
| Dec 31, 2018 | 471,773.00 |
| Sep 30, 2018 | -84,844.00 |
| Jun 30, 2018 | -13,239.00 |
| Mar 31, 2018 | -262,769.00 |
| Dec 31, 2017 | 1.61 Mn |